1. Home
  2. BB vs MESO Comparison

BB vs MESO Comparison

Compare BB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackBerry Limited

BB

BlackBerry Limited

HOLD

Current Price

$3.44

Market Cap

2.0B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.80

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BB
MESO
Founded
1984
2004
Country
Canada
Australia
Employees
N/A
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
BB
MESO
Price
$3.44
$15.80
Analyst Decision
Hold
Strong Buy
Analyst Count
5
1
Target Price
$5.12
N/A
AVG Volume (30 Days)
5.2M
270.6K
Earning Date
03-16-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
40.91
N/A
EPS
0.05
N/A
Revenue
$534,900,000.00
N/A
Revenue This Year
$4.19
$633.98
Revenue Next Year
$7.63
$29.51
P/E Ratio
$70.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$9.61
52 Week High
$5.32
$21.50

Technical Indicators

Market Signals
Indicator
BB
MESO
Relative Strength Index (RSI) 45.22 44.07
Support Level $3.34 $15.62
Resistance Level $3.59 $16.32
Average True Range (ATR) 0.11 0.52
MACD 0.03 -0.09
Stochastic Oscillator 53.09 61.03

Price Performance

Historical Comparison
BB
MESO

About BB BlackBerry Limited

BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: